Hikma Ventures

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

O7 Therapy is a digital platform dedicated to enhancing access to mental health services, primarily for Arabic-speaking individuals. Through its mobile app, the company offers online therapy, psycho-educational resources, and corporate wellness programs, facilitating a supportive environment for users on their mental wellness journey. The platform features innovative AI technology to create an engaging user experience, offering one-on-one sessions, group therapy, workshops, and webinars aimed at improving mental well-being. Additionally, O7 Therapy addresses mental health challenges in the workplace by providing Employee Wellness Programs under a B2B2E model. These initiatives focus on raising awareness, reducing stigma, and fostering safe spaces while implementing strategies to promote overall mental health in organizations.

Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.

Altibbi Ltd. operates a digital health platform catering to users and healthcare professionals in the Middle East. Founded in 2008 and based in Dubai, the platform provides comprehensive health information on various medical topics, including chronic conditions, dental health, and skin diseases. It offers a range of resources, such as a medical dictionary, articles, videos, and an encyclopedia of medicines, along with a question-and-answer feature. Altibbi also allows users to access health advice 24/7 through its website and mobile applications. Additionally, the platform facilitates the booking of video consultations with a selected group of doctors and provides translations of medical terminology into Arabic, enhancing patients' healthcare knowledge and access to professional assistance.

Activ Surgical Inc. is a digital surgery company based in Boston, Massachusetts, focused on enhancing surgical efficiency, accuracy, and patient outcomes through advanced technology. Founded in 2014, the company has developed a robotic surgery platform that integrates computer vision, artificial intelligence, and robotics to assist surgeons during complex procedures. One of its key products is the Smart Tissue Autonomous Robot (STAR), which aims to revolutionize surgical practices by improving intraoperative decision-making and reducing the risk of unintended surgical complications. The platform is scalable and patent-protected, designed to support surgeons with augmented reality and data-driven insights, ultimately making surgeries safer and more effective.

NuvoAir Medical, established in 2015 and headquartered in Stockholm, Sweden, specializes in a value-based specialty care platform for managing chronic heart and lung conditions. The company's core offering is a proactive, continuous virtual care model that combines personalized care, advanced monitoring technology, and analytics, delivered by a multidisciplinary team of healthcare professionals. NuvoAir collaborates with health plans and risk-bearing entities, employing flexible, value-based payment arrangements to reduce healthcare costs and improve patient outcomes.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

SeamlessMD is a digital patient engagement platform focused on improving health outcomes after surgery. By collaborating with healthcare providers, SeamlessMD enhances patient experiences through technology, design, and data. The platform supports hospitals in remote patient monitoring, enabling the collection of data that can lead to better surgical outcomes and reduced readmissions. Ultimately, SeamlessMD aims to deliver quality surgical care while lowering costs, addressing the challenges faced by patients and providers in the surgical process.

Lemonaid Health is an online telemedicine platform founded in 2013 and headquartered in San Francisco, California. The company aims to enhance the patient experience and optimize clinical care by utilizing advancements in machine learning and artificial intelligence. By collecting details about medical history, symptoms, current medications, and allergies, Lemonaid Health employs evidence-based guidelines to provide patients with prescriptions. This approach allows users to access quality healthcare services at a price point lower than typical co-pays, making healthcare more affordable and accessible.

Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.

WinterLight Labs Inc. is a Toronto-based company that specializes in developing a speech-based platform for detecting cognitive and mental diseases, including dementia and Alzheimer’s disease. Founded in 2015, the company utilizes artificial intelligence to analyze and quantify speech and language patterns, allowing for the accurate identification and monitoring of cognitive impairments. The platform can assess a person's cognitive, acoustic, and linguistic state from a brief one-minute speech sample, evaluating aspects such as lexical diversity, syntactic complexity, semantic content, and articulation. WinterLight Labs' technology has significant applications in clinical trials, long-term and primary care, and speech-language pathology, enabling healthcare professionals to track the progression of cognitive conditions effectively.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Propeller Health is a digital health platform focused on improving the management of chronic respiratory diseases such as asthma and COPD. The company provides a mobile application and sensors that attach to inhalers, enabling users to track their medication usage, triggers, and symptoms. This data is stored securely in a cloud-based infrastructure and facilitates personalized feedback and education for users. The platform also allows users to set medication reminders and alerts, as well as share their health data with physicians and family members. Propeller Health collaborates with various healthcare organizations and has received multiple awards for innovation in the field. Founded by David Van Sickle, Greg Tracy, and Mark Gehring, the company operates from Wisconsin, United States.

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Lemonaid Health is an online telemedicine platform founded in 2013 and headquartered in San Francisco, California. The company aims to enhance the patient experience and optimize clinical care by utilizing advancements in machine learning and artificial intelligence. By collecting details about medical history, symptoms, current medications, and allergies, Lemonaid Health employs evidence-based guidelines to provide patients with prescriptions. This approach allows users to access quality healthcare services at a price point lower than typical co-pays, making healthcare more affordable and accessible.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

Propeller Health is a digital health platform focused on improving the management of chronic respiratory diseases such as asthma and COPD. The company provides a mobile application and sensors that attach to inhalers, enabling users to track their medication usage, triggers, and symptoms. This data is stored securely in a cloud-based infrastructure and facilitates personalized feedback and education for users. The platform also allows users to set medication reminders and alerts, as well as share their health data with physicians and family members. Propeller Health collaborates with various healthcare organizations and has received multiple awards for innovation in the field. Founded by David Van Sickle, Greg Tracy, and Mark Gehring, the company operates from Wisconsin, United States.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.